Lurk...Nice to see you back in the game after throwing in the towel on RLYP just before the buyout. Felt terrible for you my man. Whatever happens do NOT sell this one !! This one will be bought out IMHO before this time next year. Patience!!
They had no RLYP as of 4/01/16
I saw you did and probably smart Lurk. Yes, still invested in a very large position at a
breakeven just under $21. I'm in as long as I see Orbimed in. When they start selling I'm out in a nano second. I've said this about a half dozen times now but I believe we will be taken before the end of the summer at a range between $28-$34.
I've been wondering the same thing since I bought it in the 12's....
Here's what I think the problem is...
The drug is meant to be used in CLL in conjunction with, or perhaps as a stand alone therapy, with Ibrut.
Ibrut of course could sell billions this year and is the leading CLL drug, however, it has some nasty side
effects that show a pretty good drop out rate over time, and a leveling off of effectiveness as well.
So where does 1202 fit in or will fit in??
Apparently serious adverse events in the last 1202 trial of 162 patients were around 8%. I think Ibrut is running around 15% or possibly a bit higher. So advantage to 1202. As far as efficacy, who knows at this juncture but probably to Ibrut given trial results to date.
So the issue is will the 1202 safety profile be enough to have it used as a SOC in combo with say Ibrut or even as a stand alone therapy? Time will tell I guess but in interim the stock continues to languish and new therapies are being developed to replace even Ibrut with the gene modification therapies so who knows?
Let's hope trial results continue to be good and somebody comes along and picks this one up.
Thanks gang for the responses. All good points. PTEK in fact filed tonight for a secondary as well. They were not going against heavy hitters in the ABX space like we did with Moxi.
Some years behind us at best and probably never.
Been discussed at some length on witter in fact. Makes a good case why SNY should buy us or even AZN.
NP in PRTK and very long CEMP but apparently they had successful Phase 3 results released on Friday for ABASSI with a clean safety profile. Heading now into trials for CABP and others. Potential competition for Soli or are they just another run of the mill antibiotic?
Yes I saw that one but thought it could have been something else. All that article said was the heart trial failed and they decided not to exercise the option. Old news.
Script numbers due out tomorrow morning as well so the short attack by Diamond is intended to be well timed...
Report will be released tomorrow on SA around 9:30AM EST. Presume he will be attacking the science of RLYP (slower mechanism of action etc) and side effects observed in some of the users such as gastric issues...diarrhea....and perhaps some a lot more serious that he's concocted, including claimed deaths.
He will likely try and draw the analogy to Orwin when he ran AFFY and had an approved drug that they marketed that was later found by the FDA to cause deaths in some cases, and the drug was taken off the market. The stock went basically to zero. I would not put it past them to attempt the same analogy here.
The point is it will be a total baseless hit piece that will sucker in some panicked longs to sell which will feed the shorts piling on, and it could get ugly. Of course Orwiin et al.wlll say nothing and will let longs just swing in the wind and fend for themselves as he always has done....
Come on genderdr...You can do better than this is trying to slam the stock.
Let's be accurate here man...Try using the Phase 2b actual study results where the dose for 130 was 1.5 mg and not 3 mg for God's sake. In order to dose the same applicable dosage pain relief you'd have to use a very unsafe dosage of morphine. The results in the Phase 2b using 1.5mg were as follows:
TRV 130.... 31% Morphine .35mg..... 53%
Vomiting......15% Morphine .35mg......42%
Nausea........41% Morphine.. .35mg.... 72%
Likewise..."AE's generally less frequent in TR130 then morphine".
Suffice it to say the pivotal Phase 3 will obviously not be using 3.5mg of TRV 130 unless the dosage is
required for a small elephant...
Seriously, probably a good call by GS. S&P at or near it's high. Had a big oil rally although the EU economic stats have been pretty bad of late. Probably due for a 5% correction right about now...
Good to know that all those articles suggesting resistantance in current ABX's are wrong and that people really aren't dying from lack of new ones. And that the US Government forcus on developing new ABX's is just wrong. I don't really care what happens so much in a test tube. It's in vivo studies that seem to matter the most and worldwide there is a MAJOR resistant evolution happening.
So you're the latest big mouth cheerleader who first posted here under your current handle on May 27th?
What type of gutless wonder does that little man? What name did you post under here before May 27th?
A $60 stock? Whatever crack you've been smoking good luck to yah!